A toxicogenomics approach was used to qualitatively and quantitatively compare the gene expression changes in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD). Hepatocytes from five individual rats and five individual humans were exposed for 24 h to 11 concentrations of TCDD ranging from 0.00001 to 100nM and a vehicle control. Gene expression changes were analyzed using whole-genome microarrays containing 13,002 orthologs. Significant changes in expression of individual orthologs at any concentration (fold change [FC] ± 1.5 and false discovery rate < 0.05) were higher in the rat (1547) compared with human hepatocytes (475). Only 158 differentially expressed orthologs were common between rats and humans. Enrichment analysis was performed on the differentially expressed orthologs in each species with 49 and 34 enriched human and rat pathways, respectively. Only 12 enriched pathways were shared between the two species. The results demonstrate significant cross-species differences in expression at both the gene and pathway level. Benchmark dose analysis of gene expression changes showed an average 18-fold cross-species difference in potency among differentially expressed orthologs with the rat more sensitive than the human. Similar cross-species differences in potency were observed for signaling pathways. Using the maximum FC in gene expression as a measure of efficacy, the human hepatocytes showed on average a 20% lower efficacy among the individual orthologs showing differential expression. The results provide evidence for divergent cross-species gene expression changes in response to TCDD and are consistent with epidemiological and clinical evidence showing humans to be less sensitive to TCDD-induced hepatotoxicity.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the prototype aryl hydrocarbon receptor (AHR) agonist for a number of polyhalogenated chlorinated dioxins and furans (PCDDs/Fs) and polychlorinated biphenyls. TCDD is formed by both natural and anthropogenic processes including the incineration of chlorinecontaining substances, bleaching of paper, manufacturing of specific organochlorine chemicals, volcanoes, and forest fires (Environmental Protection Agency [EPA], 2006) . Exposure to TCDD is known to produce an array of biochemical and physiological effects in laboratory animals that includes cancer, endocrine alterations, immunological effects, and developmental defects (Birnbaum, 1994; Pohjanvirta and Tuomisto, 1994) . The biochemical and physiological responses to TCDD are highly variable between species and even among different strains within a species (Budinsky et al., 2010; Carlson et al., 2009; Flaveny et al., 2010; Okey, 2007) . The inter-and intraspecies differences among animal models confound the issue of extrapolating the responses to humans (Boutros et al., 2008; Carlson et al., 2009; Flaveny et al., 2010) .
Most, if not all, of the biological effects of TCDD are mediated by the AHR (Bunger et al., 2003 (Bunger et al., , 2008 Peters et al., 1999) . The AHR is a ligand-activated transcription factor and a member of the basic helix-loop-helix, per/ARNT/Sim (PAS) superfamily. The unliganded form of the AHR exists in the cytoplasm in a stable complex with HSP90, the AHRinteracting protein, and p23 (Petrulis and Perdew, 2002) . Following binding of TCDD, the AHR translocates to the nucleus and binds with the AHR nuclear translocation protein (ARNT). The AHR:ARNT heterodimer binds to xenobiotic response elements (XREs) (Denison et al., 1988) and regulates a diverse set of genes (Hankinson, 1995; Hsu et al., 2007; Kolluri et al., 1999; Poland and Knutson, 1982; Thomsen et al., 2004) . Extensively characterized AHR-regulated genes include Cyp1a1, Cyp1a2, Cyp1b1, Nqo1, Aldh3a1, Ugt1a2, Gsta1, and Tiparp (Boutros et al., 2008; Diani-Moore et al., 2010; Tijet et al., 2006) . Although it is widely believed that the majority of biological effects resulting from AHR ligand activation are driven through direct binding to XREs (Bunger Disclaimer: The authors certify that all research involving human subjects was done under full compliance with all government policies and the Helsinki Declaration. et al., 2008) , regulation of the AHR through protein interactions and other nongenomic mechanisms has been proposed as alternative routes for the downstream effects. For example, ligand activation of the AHR has been shown to induce proteosome degradation of estrogen receptor-a (ER-a), thereby reducing the ability of the cell to respond to estrogens (Wormke et al., 2003) . Additionally, the AHR can repress acutephase gene expression by inhibiting the recruitment of RELA and C/EBPB to the promoters of target genes (Patel et al., 2009) . Other nongenomic effects of the AHR have been proposed in regulating the Cullin-4B (Ohtake et al., 2009) , mitogen-activated protein kinase (Tan et al., 2002) , cyclin-dependent kinase 4 (Barhoover et al., 2010) , protein kinase A (Dong and Matsumura, 2009) , and SRC (Dong and Matsumura, 2009; Haarmann-Stemmann et al., 2009) 
signaling pathways.
Comparative biology is an important tool for understanding organism diversity and inferring conservation of phenotypic responses across species. In toxicology, animal models are widely used to infer human responses to chemical exposures. However, the reliance on animal models necessitates the application of comparative biological tools to determine whether a particular adverse response will be conserved in humans. Assessing the cross-species conservation of a response typically involves an understanding of the key molecular events and an assessment of whether the processes and components that comprise those events are present in both the model species and humans. On a gene basis, the conserved components between species are referred to as orthologs (Koonin, 2005) . By definition, orthologs are genes in different species that evolved from a common ancestral gene and normally retain the same function throughout the course of evolution. By comparing expression changes among orthologous genes following dose-response treatment of a chemical, the question of human relevance may be examined as well as potential differences in sensitivity between rodents and humans. Conserved responses may differ in magnitude between species, but if the differences are consistent, then appropriate adjustment factors can be derived for cross-species inferences (National Research Council, 2007) .
In this study, adult female rat and human female primary hepatocytes were exposed to TCDD at concentrations ranging from 0.00001 to 100nM (11 treatments spanning seven orders of magnitude). Whole-genome microarrays were used to assess similarities and differences in gene expression among orthologous genes across the two species. The results showed that TCDD produces divergent gene expression profiles in rat and human hepatocytes when examined on both an ortholog or pathway basis. Based on the dose-response changes, human hepatocytes are approximately 15-fold less sensitive than rat hepatocytes when evaluated based on commonly affected orthologs or signaling pathways. Human hepatocytes also showed a lower efficacy across commonly affected orthologs.
MATERIALS AND METHODS
Chemicals and reagents. Phosphate-buffered saline was purchased from Invitrogen (Gibco, Grand Island, NY). ITSþ supplement was purchased from BD Biosciences (San Jose, CA). Dulbecco's Minimal Essential Medium (DMEM), DMEM-Ham's F12, Hank's Balanced Salt Solution (HBSS), and dimethylsulfoxide (DMSO) were obtained from Sigma Chemical Co. (St Louis, MO). TCDD was 98% pure and was synthesized at the Dow Chemical Company.
Isolation of primary hepatocytes. Primary cultures of human hepatocytes were prepared from remnants of normal resected liver tissue from five women aged 44-77 years (Table 1 ). The choice of only females was made based on the use of female rats in the 2-year cancer bioassay (National Toxicology Program [NTP], 2006) . Each donor was fully consented under an institutional review board application approved by the individual institutions where liver resection surgery was conducted. The resected liver tissue was determined to be disease free by a board-certified pathologist. Four of the five human donors did not consume alcohol and all were free of hepatitis and HIV. The research on the human samples was carried out in accordance with the principles of the current version of the Helsinki Declaration. The primary cultures of rat hepatocytes were obtained from five individual 10-week-old female Sprague Dawley rats. Each individual human and individual rat preparation were treated as a biological replicate. Preplating cell viability, determined by Trypan Blue exclusion, ranged from 82 to 93% in human and 90 to 94% in rat hepatocytes.
Following isolation, hepatocytes were resuspended in DMEM containing 5% fetal calf serum, insulin (4 ng/ml), and dexamethasone (100nM). The hepatocytes were then added to 24-well BioCoat (BD Biosciences) plates coated with collagen type 1 substratum and allowed to attach for 3-6 h at 37°C in a humidified chamber with 95% relative humidity and 5% CO 2 . After attachment, the culture plates were swirled, and the medium containing debris and unattached cells were aspirated. Fresh ice-cold serum-free DMEM/Ham's F12 medium containing 50nM dexamethasone, 6.25 ng/ml insulin, 6.25 ng/ml transferrin, 6.25 ng/ml selenium (ITSþ), and 0.25 mg/ml Matrigel was added to the culture plate and immediately returned to the humidified chamber. Dexamethasone has very similar biological activity compared with endogenous cortisol and was used due to its > 103 higher potency and longer half-life relative to cortisol, allowing it to be used at low concentrations to minimize unintended effects (Ballard et al., 1975; Meikle and Tyler, 1977) . The same dexamethasone concentration was used for rat and human cells because their resting plasma cortisol levels are very similar ranging from 138 to 552nM in humans and 248 to 414nM in rats (Guillemin et al., 1958; Norman and Litwack, 1986) . Serum-free medium was used because serum can significantly reduce the cellular uptake of TCDD (Hestermann et al., 2000) and contains naturally occurring AHR agonist activity that may confound observations (Connor et al., 2008; Schecter et al., 1999) . Medium was kept in the dark prior to use and was not changed during the incubation periods.
Cell viability and incubations with TCDD. Stock solutions of TCDD (100lM) were diluted in DMSO and added to culture media (DMEM-Ham's F12) to a final DMSO concentration of 0.1%. The human and rat hepatocyte cultures were exposed for 24 h to the DMSO vehicle (0.1%) or one of the following TCDD concentrations: 0.00001, 0.0001, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 10, and 100nM. Cell viability was examined at the 24-h time point in the vehicle control hepatocytes and hepatocytes treated with 100nM TCDD. Viability was assessed by morphological appearance, lactate dehydrogenase leakage (CytoTox-ONE; Promega, Madison, WI), adenosine triphosphate levels (CellTiterGlo; Promega), and phase contrast microscopy (LeCluyse et al., 2000; Meunier et al., 2000) . Cell viability endpoints did not demonstrate treatment-related cytotoxicity.
Gene expression microarray measurements. Cells (24-well format) were washed with 1 vol of HBSS, lysed by addition of 0.35 ml of ABI PRISM Nucleic Acid Lysis Solution (Applied Biosystems, Foster City, CA), and frozen at À70°C. Lysates were thawed, and total RNA was isolated from each sample using an ABI PRISM 6100 Nucleic Acid PrepStation according to the manufacturer's protocol. RNA was further concentrated and buffer exchanged using a Qiagen RNeasy kit per the manufacturer's protocol. Global gene expression changes were measured using Agilent rat and human whole genome 4 3 44 K oligonucleotide microarrays that contain > 41,000 60-mer oligo probes. The microarrays were processed using a one-color format. For each sample, Alexa Fluor 555-labeled complementary RNAs (cRNAs) were generated from 500 ng of total RNA using the Epicentre TargetAMP 1-Round Aminoallyl-cRNA Amplification Kit per the vendor's protocol (Epicentre Biotechnologies, Madison, WI). The Aminoallyl-cRNA was then purified using Qiagen RNeasy Mini Elute Kit. On each microarray, 1.65 lg of labeled cRNA was hybridized for 17 h and subsequently washed per the Agilent protocol. Microarrays were scanned using the Agilent dual laser DNA microarray scanner, model G2565AA, with 5 lm resolution. A total of five biological replicates (hepatocytes from individual rats and humans) were performed at each concentration in each species except for the rat at 0.03nM where four biological replicates were obtained. The gene expression data have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (Accession No.: GSE34251).
Gene expression data analyses. The gene expression data were normalized based on the median signal values and log 2 transformed. The probes were then filtered to remove those with signal values at or below background level by selecting those probes where the Agilent flag ''IsWellAboveBG'' was true in at least four of five replicates for any one of the 12 treatments (DMSO vehicle þ 11 TCDD concentrations). The ''IsWellAboveBG'' flag is true when the feature intensity is positive and at least 2.6 SDs above background. The filtering was performed in GeneSpring GX (Version 11.5; Agilent, Santa Clara, CA). Because hepatocytes from the same animal or individual human were exposed to each of the 12 treatments, statistical analysis of the data in each species was performed using a two-way ANOVA with concentration as a fixed effect and the animal/individual identifier as a random effect (Partek Genome Suite 6.5; Partek Incorporated, St Louis, MO). Linear contrasts were performed between each concentration and the vehicle control. The p values were adjusted for multiple comparisons using false discovery rate (FDR) (Benjamini and Hochberg, 1995) . Ortholog matching and comparison were performed using GEAX 1.3b (http:// sourceforge.net/projects/geax/). The annotated probes in both species were matched to their Entrez gene ID numbers, and orthologs were identified using Homologene. Gene set enrichment analysis was conducted using the GeneGo pathway maps in the Metacore database (Version 6.4, build 26113; GeneGo, St Joseph, MI). The enrichment p values were calculated based on a hypergeometric distribution with the GeneGo database used as the background. Significant enrichment was defined as a false discovery corrected p value < 0.05.
Benchmark dose (BMD) analyses of the gene expression microarray data were performed as previously described Yang et al., 2007) with modification. The log 2 -transformed expression values for each probe were fit to a series of five different dose-response models-Hill, power, linear (1°), polynomial 2°, and polynomial 3°. Each model was run assuming constant variance, and the benchmark response factor was set to 1.349 multiplied by the SD in control animals to estimate a BMD with a 10% increase in tail area Yang et al., 2007) . The power model was restricted to power !1. For model selection, a nested likelihood ratio test was performed on the linear, polynomial 2°, and polynomial 3°models. If the more complex model provided a significantly improved fit (p < 0.05), the more complex model was selected. The simpler model was selected if the more complex model did not provide a significantly improved fit (p ! 0.05). The Akaike information criterion (AIC) for the selected polynomial model was then compared with the AIC for the Hill and power models. The model with the lowest AIC was selected as the final model except in cases where the ''k'' parameter for the Hill model was less than one-third the lowest treatment concentration (0.00001nM). In the cases where the k parameter for the Hill model was out of bounds, the Hill model was excluded from the final selection. The final selected model was used to calculate a BMD and benchmark dose lower confidence limit (BMDL). To avoid model extrapolation and any potential bias from poor fitting genes, probes with a BMD value greater than the highest treatment concentration (100nM) or a goodness-of-fit p value < 0.1 were removed from further analysis. The remaining probes were converted into unique genes based on their NCBI Entrez Gene ID. When two or more probe sets were associated with a single gene, the BMD and BMDL values for the individual probes were averaged to obtain a single BMD and BMDL value. The Entrez Gene identifiers were then matched to their corresponding canonical signaling pathways using the GeneGo Metacore database (GeneGo). The median BMD and BMDL values were used to summarize each signaling pathway. The canonical signaling pathways included the GeneGo pathway maps with the additional ToxHunter pathways.
RESULTS

Cross-species Analysis of Differentially Expressed Probes and Orthologs
In the human samples, a total of 31,865 probes (16,594 genes) were identified as expressed above background in at least four of the five replicates in any of the 12 treatments (DMSO þ 11 TCDD concentrations). In the rat samples, a total of 24,872 probes (12,095 genes) were identified as expressed above background based on the same criteria. Because hepatocytes from a single animal or individual were exposed to all treatment concentrations, a two-way ANOVA was performed on the filtered probes with concentration as a fixed effect and the animal/individual identifier as a random effect. Linear contrasts were then performed between each concentration and the vehicle control. The p values were adjusted for multiple comparisons using FDR (Benjamini and Hochberg, 1995) . The numbers of significantly altered probes at each concentration are provided in Table 2 . Statistically significant changes in expression were observed at the 0.01nM concentration in human hepatocytes, whereas rat hepatocytes showed significant changes beginning at the lowest concentration (0.00001nM). The number of significantly altered genes was variable from 0.00001 to 0.01nM where a monotonic increase was observed. The significant genes identified from 0.00001 to COMPARE GENETIC EXPRESSION IN HUMAN AND RAT HEPATOCYTES 201 0.01nM were not consistent between concentrations suggesting that these changes were not concentration related. The addition of a fold change (FC) cutoff (> 61.5) had little impact on the number of significantly altered probes and genes at the lower doses but had a progressively larger impact at the higher doses.
Among the 16,594 human and 12,095 rat genes expressed above background, 9356 were orthologous between the two species. When analyzed statistically, the dose-response changes in the number of differentially expressed orthologs closely paralleled that observed among all the probes (Table 2) . In general, the number of differentially expressed orthologs was monotonic in both species, and the addition of an FC cutoff (> 61.5) had little impact at the lower end of the dose-response curve. Visualization of the union of differentially expressed orthologs in both species using hierarchical clustering showed significant discordant cross-species expression (Fig. 1) . When analyzed using a Venn diagram, only 159 human and 158 rat orthologs were in common (Fig. 2) . The common orthologs amounted to approximately 33% of the significantly altered orthologs in the human hepatocytes and 10% of the significantly altered orthologs in the rat. Among the common orthologs, 47 showed significant upregulation and 50 showed significant downregulation in both species. A total of 62 of the common orthologs were discordantly expressed.
Cross-species Analysis of Enriched Signaling Pathways
To evaluate the cross-species conservation in gene expression at the pathway level, the orthologs showing differential expression in each species were used to perform pathway enrichment analysis. The enriched pathways were then compared between species resulting in a total of 12 pathways that were commonly enriched (FDR < 0.05) (Fig. 3) . The common pathways amounted to approximately 24% of the enriched pathways in humans and 22% of the enriched pathways in rats. Among the conserved pathways, multiple nuclear receptors were present including the constitutive androstane receptor (CAR), pregnane X receptor (PXR), androgen receptor, and ER (Table 3 ). In addition, the regulation of epithelial to mesenchymal transition (EMT), stellate cell activation, macropinocytosis, leptin signaling, endothelial nitric oxide synthase signaling, and cytoskeletal remodeling pathways were enriched in both human and rat hepatocytes. The genes included in the 12 significantly enriched pathways were compared to determine the number of unique genes represented and which were concordantly or discordantly regulated across species (Supplementary file 4). There were 94 genes and 46 genes regulated within the 12 pathways in rat and human primary hepatocytes, respectively. Of these, 19 genes were common to rats and humans with 16 genes concordantly regulated and 3 genes discordantly regulated.
For species-specific enrichment, a total of 37 were enriched in human hepatocytes, but not in rat, and 42 were enriched in rat hepatocytes, but not in humans. Among the pathways that were enriched only in human hepatocytes, a number of growth factorrelated pathways were present, including epidermal growth factor receptor, hepatocyte growth factor, platelet-derived growth factor, and transforming growth factor-b (TGF-b) (Table 4 ). In addition, several metabolic pathways were also enriched only in human hepatocytes including retinol metabolism, pyruvate metabolism, and testosterone biosynthesis and metabolism. Transcription factors that were only enriched in the human hepatocytes included CREB, PPAR, NRF2, and ChREBP. Among the pathways that were enriched only in rat hepatocytes, a wide variety of immune responses were present including the interleukin (IL)-1, cytokine production by Th-17 cells, IL-6, IL-9, IL-12, CD40, C-X-C chemokine receptor type 4, tumor necrosis factor receptor 1, interferon-c, and IL-3 signaling pathways (Table 5 ). In addition, specific metabolic pathways related to glycolysis and gluconeogenesis and fructose metabolism were enriched in the rat hepatocytes. The endoplasmic reticulum stress response pathway was also enriched in rat hepatocytes, but not humans. Other pathways enriched in a species-dependent manner are provided in Tables 4 and 5 .
Cross-species Differences in Potency BMD methods have been widely used to estimate points of departure for apical end points in chemical risk assessment (EPA, 1995) and for transcriptomic responses (Andersen et al., (4) 2 (1) 6 (1) 1 (1) 14 (7) 64 (29) 1774 (808) 2068 (930) 3265 (1542) 4429 (2064) 5059 (2472) FC > ±1.5 and FDR < 0.05 11 (4) 2 (1) 6 (1) 1 (1) 14 (7) 55 (26) 1181 (481) 1460 (598) 2032 (898) 2628 (1150) 2881 (1333) a Total number of probes (orthologous and nonorthologous). 2010; Bercu et al., 2010; Thomas et al., 2007 Thomas et al., , 2011 . The BMD corresponds to a dose or concentration that causes a defined change in a potential adverse response and, therefore, represents a measure of potency. In addition, because the BMD values are typically used as points of departure for risk assessment, they would also represent the best basis for crossspecies comparisons of potency. The BMD values for five common AHR-regulated genes are shown in Table 6 . Among the 159 orthologs that showed common differential expression in both species (Fig. 2) , the most sensitive gene was CYP1A1 with a human and rat BMD of 0.0026 and 0.0005nM, respectively. To more broadly examine cross-species differences in potency, BMD values were estimated for all 9356 orthologs that were expressed above background. A total of 733 human orthologs were identified that had BMD values less than the highest dose (< 100nM) and a goodness-of-fit p value > 0.1. In the rat hepatocytes, a total of 1591 orthologs were identified that had BMD values based on the same criteria. The median BMD values for the human and rat orthologs were 12.07 and 0.24nM, respectively (Figs. 4A and 4B). The distributions of the human and rat ortholog BMD values were statistically different based on a nonparametric Mann-Whitney U test (p < 0.0001). The human:rat BMD ratio was calculated for each ortholog. In comparing the human:rat BMD ratio for the intersection of the orthologs that had BMD values in both species, the human hepatocytes were approximately 18-fold less sensitive on average (Fig. 4C) . In order to compare the union of orthologs that had a BMD value in either species, if an ortholog had a defined BMD value (BMD less than the highest dose and goodness-of-fit p value > 0.1) in one species and not the other, the species without the defined BMD value was given an arbitrary BMD equal to the highest dose (100nM) to allow calculation of the ratio. Among the union of orthologs, the human hepatocytes were more than sevenfold less sensitive on average (Fig. 4D) . A complete list of all human and rat ortholog BMD values is provided in Supplementary file 2.
In biological systems, individual components such as proteins and small molecules are organized into signaling pathways to regulate cellular function. To assess cross-species differences in potency at the level of signaling pathways, the individual orthologs were grouped into known signaling pathways, and the median BMD was calculated for each pathway . In the human hepatocytes, a total of 208 pathways had more than three genes with a BMD values less than the highest dose (< 100nM) and a goodness-of-fit p value > 0.1. In the rat hepatocytes, a total of 508 pathways had more than three genes using the same criteria. The median BMD values for the human and rat pathways were 10.63 and 0.39nM, respectively (Figs. 5A and 5B). The distributions of the human and rat pathway BMD values were statistically different based on a nonparametric Mann-Whitney U test (p < 0.0001). The human:rat BMD ratio was calculated for each pathway. In comparing the human:rat BMD ratio for the intersection of the pathways that had at least three genes with a defined BMD value in both species, the human hepatocytes were approximately 15-fold less sensitive on average (Fig. 5C) . In order to compare the union of pathways that had a BMD value in either species, if a pathway had a defined BMD value (at least three genes with a BMD less than the highest dose and goodness-of-fit p value > 0.1) in one species and not the other, the species without the defined BMD value was given an arbitrary BMD equal to the highest dose (100nM) to allow calculation of the ratio. Among the union of pathways, the human hepatocytes were > 80-fold less sensitive (Fig. 5D) . The most sensitive pathways in the human and rat hepatocytes are provided in Table 7 . A complete list of all human and rat pathway BMD values is provided in Supplementary file 3.
Cross-species Differences in Efficacy
Efficacy is broadly defined as the maximal effect that a substance is capable of producing in a biological system. To compare cross-species differences in efficacy, the maximum absolute value of the FC in each species was obtained for all orthologs showing an FC > ±1.5 and FDR < 0.05 in at least one dose (i.e., the number of significant orthologs in each species in Fig. 2) . The absolute value of the maximum FC was used since gene expression changes can be either direction. The median of the maximum absolute value FC for the human and rat orthologs was 1.66 and 1.78, respectively (Figs. 6A and 6B). The human and rat maximum absolute value FC distributions were statistically different based on a nonparametric Mann-Whitney U-test (p < 0.0001). The human:rat ratio of the maximum absolute value FC was calculated for each ortholog. In comparing the human:rat maximum FC ratio for the intersection of the orthologs that were differentially expressed (i.e., intersection of Venn diagram in Fig. 2) , the human hepatocytes were approximately 0.8-fold or 20% less sensitive (Fig. 6C) . Similar results were obtained with the union of differentially expressed orthologs with human hepatocytes 0.74-fold or 26% less sensitive (Fig. 6D) .
DISCUSSION
The dose-dependent alterations in messenger RNA (mRNA) expression were assessed in primary adult hepatocytes from five women and five female Sprague Dawley rats exposed to 11 concentrations of TCDD for 24 h. Changes in mRNA expression for individual orthologous genes and for cellular signaling pathways were compared using both traditional ANOVA and BMD modeling approaches. Based on the ANOVA approach, rat hepatocytes showed significant alterations beginning at a lower dose and a larger number of significantly altered genes overall. These differences are not due to faster elimination of TCDD in rat cells as TCDD is not readily metabolized in either species, having a half-life ranging from approximately 11-45 days in rats and 3-10 years in humans (Aylward et al., 2005; Emond et al., 2006) . In comparing the cross-species changes in expression, approximately 33% of the significantly altered human orthologs were also altered in the rat hepatocytes, whereas only 10% of the significantly altered rat orthologs were altered in the human hepatocytes. The results are consistent with previous studies looking at cross-species differences in hepatocyte responses to TCDD. Carlson et al. (2009) described divergent gene expression changes in rat and human hepatocytes when comparing approximately 4000 orthologous genes measured using Affymetrix microarrays. Divergent gene expression changes were also obtained in vivo in the mouse and rat liver or among different rat strains following exposure to TCDD (Boverhof et al., 2006; Moffat et al., 2010) . In the mouse and rat livers, only 33 of 3087 orthologs (1.1%) were commonly affected by TCDD (Boverhof et al., 2006) . Among the different rat strains, only 32% of TCDD-responsive genes were altered in the liver of more than one of four rat strains/ lines (Moffat et al., 2010) . The data in this study draw from a broader pool of orthologous genes with a more comprehensive dose-response.
The human and rat primary hepatocytes were cultures using current state of the art techniques developed over several decades for culturing of primary hepatocytes (Swift et al., 2010) . The isolation of the hepatocytes and the subsequent culture conditions for maintenance and treatment of the human hepatocytes and the rat hepatocytes were identical. Even so, because the experiments were conducted on a single liver cell type under in vitro conditions, the effects observed are conditional and there is potential for confounding, thereby introducing some bias into the observed effects with the introduction of additional uncertainty in the fidelity for replicating in vivo responses. For example, the culture media contained low levels of dexamethasone, a synthetic corticosteroid, and insulin, transferrin, and selenium; the latter three are found as normal serum constituents. Although isolation and initial plating of the hepatocytes were done in the presence of serum, TCDD treatment was done under serum-free conditions to maximize cellular uptake of TCDD. There are reports that AHR expression and regulated genes that may be affected by corticosteroid treatment and even differentially in rat and human hepatocytes (Bielefeld et al., 2008; Harper et al., 2006; Linder et al., 1999; Monostory et al., 2005 Monostory et al., , 2009 Vrzal et al., 2009 ). In addition, serum contains many factors that can impact cellular signaling, including a relatively high level of AHR activity in blood that is not attributable to PCDDs/Fs (Connor et al., 2008; Schecter et al., 1999) . The potential for confounding from hormones, serum, nutrients, and a host of other factors present in culture media is an unavoidable limitation to in vitro models, whether they be primary cells or established cell lines, and this must be factored into any interpretation of the observations. Still, the culture conditions used here have maintained functional AHR-mediated responses based on observations reported separately of the well-characterized AHR-regulated core genes CYP1A1 and CYP1A2 (Budinsky et al., 2010) . TCDD induction of CYP1A was generally consistent with those from other studies of primary human hepatocytes cultured under a variety of conditions (Bunger et al., 2008; Drahushuk et al., 1996 Drahushuk et al., , 1998 Kishida et al., 2008; Richert et al., 2009; Schrenk et al., 1995; Silkworth et al., 2005; Vrzal et al., 2008 Vrzal et al., , 2009 Xu et al., 2000) . A previous study demonstrated limited cross-species conservation on an individual gene basis following exposure to 
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PPARa agonists but showed greater conservation at the level of the pathway (Rakhshandehroo et al., 2009) . To evaluate the cross-species conservation in gene expression at the pathway level, the orthologs showing differential expression in each species were used to perform pathway enrichment analysis. The significantly enriched pathways were then compared For genes with more than one probe, goodness-of-fit p values were shown for each probe. The corresponding BMD and BMDL values were averaged to obtain a single BMD and BMDL .   FIG. 4 . Histograms of the cross-species differences in potency related to changes in ortholog expression. (A) Histogram of the BMD values for the 620 human orthologs that had a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1. Median, upper quartile (UQ), and lower quartile (LQ) values are shown in the inset table. (B) Histogram of the BMD values for the 1588 rat orthologs that had a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1. Median, UQ, and LQ values are shown in the inset table. (C) Histogram of the log 2 ratio (human:rat) of the BMD values for human and rat orthologs which had a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1 in ''both'' species (intersection of orthologs in A and B). Median, UQ, and LQ values are shown in the inset table. (D) Histogram of the log 2 ratio (human:rat) of the BMD values for human and rat orthologs which had a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1 in ''either'' species (union of orthologs in A and B). If an ortholog had a defined BMD value (BMD < highest dose and goodness-of-fit p value > 0.1) in one species and not the other, the species without the defined BMD value was given an arbitrary BMD equal to the highest dose (100nM) to allow calculation of the ratio. Median, UQ, and LQ values are shown in the inset table. between species. The commonly enriched pathways amounted to approximately 24% of the total enriched pathways in human hepatocytes and 22% of the total enriched pathways in rats. As a result, the percentage of conserved pathways was less than the percentage of conserved orthologs for human hepatocytes, but the percentage of conserved pathways was greater than the percentage of conserved orthologs for rat hepatocytes. Nonetheless, pathway enrichment analysis provides the ability to functionally interpret both the conserved and species-specific expression changes. Among the pathways that were enriched in both species, the AHR signaling pathway and a number of nuclear receptor pathways that lead to the induction of metabolic enzymes were identified. The enrichment in metabolic-related function was similar to that observed in the previous cross-species studies (Boverhof et al., 2006; Carlson et al., 2009; Moffat et al., 2010) and indicates cross-species conservation in AHR nuclear receptor cross talk and the regulation of associated metabolic enzymes. Interestingly, stellate cell activation and fibrosis, EMT, cellular uptake by macropinocytosis, and cytoskeletal remodeling pathways were also conserved across species. The AHR has been previously shown to be involved in regulating hepatic fibrosis through regulation of latent TGF-b-binding protein-1 (LTBP-1) (Corchero et al., 2004) . In contrast, a variety of pathways were enriched in a single species including many involved in growth factor signaling, apoptosis, energy metabolism, specific transcription factors, and the immune response and suggest that the function of the AHR in regulating these specific pathways has diverged in humans and rats. In particular, the enrichment of immune response, endoplasmic reticulum stress, and apoptotic pathway in the rat hepatocytes could have implications for extrapolating associated effects observed in rodents to humans. TCDD-induced hepatic immune cell-mediated inflammation and necrosis are a common observation in mice and Histogram of the BMD values for the 508 rat pathways which had more than three genes with a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1. Median, UQ, and LQ values are shown in the inset table. (C) Histogram of the log 2 ratio (human:rat) of the BMD values for human and rat pathways which at least three genes with a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1 in ''both'' species (intersection of pathways in A and B). Median, UQ, and LQ values are shown in the inset table. (D) Histogram of the log 2 ratio (human:rat) of the BMD values for human and rat pathways which at least three genes with a BMD value less than the highest experimental TCDD dose (100nM) and a goodness-of-fit p value > 0.1 in ''either'' species (union of pathways in A and B). If a pathway had a defined BMD value (at least three genes with a BMD value less than the highest dose and goodness-of-fit p value > 0.1) in one species and not the other, the species without the defined BMD value was given an arbitrary BMD equal to the highest dose (100nM) to allow calculation of the ratio. Median, UQ, and LQ values are shown in the inset table.
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to a more limited degree in rats (Chang et al., 2005; Hailey et al., 2005) , whereas evidence of hepatic injury in humans, even humans with the highest recorded TCDD exposures, is mild and transient or absent (Bond et al., 1983; Geusau et al., 2001; Mocarelli et al., 1986; Pocchiari et al., 1979) . Alterations of these pathways are consistent with the TCDD-induced hepatotoxicity and liver tumors observed in rats, whereas these pathways were not affected in cells from humans who do not develop hepatotoxicity and liver tumors when exposed to TCDD (Connor and Aylward, 2006) .
Apart from the signaling pathways affected by TCDD in hepatocytes, cross-species differences in potency were examined at multiple levels of biological organization using a BMD approach. The typical battery of AHR-regulated genes showed cross-species differences in potency ranging from 2.41-fold for CYP1A2 to 6.96-fold for TIPARP with human hepatocytes having higher BMD values for each ortholog. When evaluated across all human and rat orthologs with a defined BMD, the human hepatocytes were less sensitive with a median difference of 18-fold. Similar results were obtained when the doseresponse changes were analyzed at the level of signaling pathways; however, this can be expected because the signaling pathways merely group the existing genes. A central difficulty in understanding the effect of TCDD is that few of the shortterm transcriptional changes can be directly associated with any of the biological manifestations of TCDD exposure. Only a handful of AHR target genes have been proven to be directly linked to downstream adverse effects at the level of the cell or tissue. For example, TCDD-mediated induction of TIPARP in hepatocytes has been functionally linked to the suppression of gluconeogenesis (Diani-Moore et al., 2010) . Similarly, TCDDmediated induction of Bach2 in B cells has been functionally linked to suppression of IgM secretion (De Abrew et al., 2011) . For these genes, a cross-species comparison of potencies could provide a direct estimate of the relative species sensitivities for the adverse effects. By comparison, a cross-species comparison on the level of the transcriptome will potentially contain transcriptional changes associated with both adaptive and adverse effects. Nonetheless, the results suggest that human hepatocytes are inherently less sensitive to the effects of TCDD than rat hepatocytes.
Although this study's objective was not specifically to evaluate the mode of action (MOA) of TCDD with respect to liver cancer development, a few of the gene changes may potentially relate to histopathological changes reported in cancer bioassays (Chang et al., 2005; Hailey et al., 2005) . For example, Hailey et al. (2005) identified an important series of dose-related histopathological observations following an extensive pathology working group assessment of the 2006 NTP cancer bioassay that may be relevant to the genomic changes observed in our study. At the high dose of TCDD in the NTP study (100 ng/kg/day), fatty changes, bile duct fibrosis and hyperplasia, inflammation, and cholagiofibrosis were clearly observed by 53 weeks. By 2 years, oval cell hyperplasia was statistically increased beginning with the lower dose of 22 ng/ kg/day. Multinucleated hepatocyte increases were observed as early as 31 weeks into the study at doses of 46 and 100 ng/kg/ day. The histopathological changes identify an important role for oval cell proliferation giving rise to biliary/portal duct hyperplasia cholangiolar carcinoma and hepatocellular carcinoma. The notable increase in multinucleated hepatocytes may be a biomarker for the development of less aggressive hepatocellular adenomas or evidence of delayed hepatocyte replication that would stimulate oval cell (rat hepatic stem cells) proliferation and differentiation to replace hepatocytes lost to apoptosis. Although a full exploration of all potential gene changes, pathways, and cell signaling observations that could be hypothetically linked to cancer bioassay histology is beyond the scope of this paper, a few examples such as the enrichment in pathways related to stellate cell activation and liver fibrosis signaling pathways, EMT, apoptosis and survival, cell cycle regulation, and cross talk with other nuclear receptors (CAR/PXR) serve as discussion points. Stellate cell involvement with liver fibrosis, retinoid metabolism, and control of hepatic progenitor cell regeneration is a potential key event that is consistent with the histopathological changes induced by TCDD in rodent liver (Forbes and Parola, 2011; Pintilie et al., 2010; Senoo et al., 2010; Shmarakov et al., 2010) . However, it would have to be evaluated whether similar gene changes occur in stellate cells or if these gene changes in hepatocytes translate to changes in stellate cells that would be in close proximity in the liver acinus. Genes and signaling pathways related to the cell cycle are critical to tumor promotion. The rat hepatocytes demonstrated a negative twofold change in expression of cyclin D1 and enrichment in the cell cycle pathway related to the G 1 /S transition that could contribute to the cell cycle and liver regeneration delays reported in the literature (Barhoover et al., 2010; Bauman et al., 1995; Elferink et al., 2001; Hushka and Greenlee, 1995; Levine-Fridman et al., 2004; Mitchell et al., 2006) . The EMT signaling is relevant because EMT has been linked to fibrosis, fibroblast formation, and tumor progression via changes in epithelial plasticity, all of which has been observed with TCDD in rodent liver (Huber et al., 2005; Kolluri et al., 1999) . AHR activation altering EMT pathways could contribute to cholangiofibrosis and cholangiocarcinoma. Cross talk with other nuclear receptors that are likewise involved with rodent tumor promotion can be more globally thought of as a nuclear receptor MOA (Shah et al., 2011) . These putative links between AHR-induced changes in gene transcription and the key events and MOA for sustained AHR activation-induced liver tumor promotion are speculative given the nature of the study design but serve to focus hypotheses and additional research for understanding key events and MOA.
Although the relative potencies following TCDD treatment may be mix of transcriptional changes related to both adaptive and adverse effects of AHR signaling, the reduced sensitivity of human hepatocytes to TCDD is consistent with previous experimental observations of involving ligand affinity and regulation of CYP1A1 and CYP1A2 expression and activity. For ligand binding, the human AHR shows approximately a 30-fold reduced affinity for TCDD compared with the rat receptor (Denison et al., 1986; Lorenzen and Okey, 1991) . For the induction of CYP1A2 and CYP1A1 mRNA, human hepatocytes were 30-and 5-fold less sensitive than rats, respectively (Budinsky et al., 2010) . Similar differences in sensitivity have been observed in vivo where individuals exhibited elevations in CYP1A2 at body burdens above 750 ng TCDD equivalents per kilogram body weight while laboratory rodent models require lower body burdens < 50 ng/kg body weights for CYP1A2 induction (Connor and Aylward, 2006) . The regulation of the CYP1A1 mRNA is consistent with enzymatic activity where human hepatocytes displayed approximately 4-to 48-fold lower sensitivity compared with primary rat hepatocytes (Schrenk et al., 1991 (Schrenk et al., , 1995 Silkworth et al., 2005; Xu et al., 2000) .
The cross-species differences in efficacy were less dramatic than those observed in potency. The median difference in efficacy among orthologs showing differential expression in both species was only 20% lower in humans. The potential reasons for the lower cross-species differences in efficacy may include both technical and biological explanations. On a technical basis, gene expression microarrays tend to have a reduced dynamic range for highly induced genes. Support for this explanation comes from a previous study of TCDD-induced changes in gene expression measured using quantitative reverse transcription polymerase chain reaction (Budinsky et al., 2010) . In that study, CYP1A1 and CYP1A2 expression showed a baseline-adjusted efficacy that was 163-and 77-fold higher in human hepatocytes compared with rat. In our study, CYP1A1 and CYP1A2 expression showed a baseline-adjusted efficacy that was 3.8-and 2.3-fold higher in human hepatocytes than in rat. Although the cross-species differences were qualitatively similar, the microarray results were lower in magnitude.
In this study, a comprehensive analysis of transcriptomic changes in human and rat hepatocytes was performed to identify similarities and differences at both the individual gene and pathway levels. This study is one of only a handful of studies conducted in normal human primary cells exposed to TCDD and is an important contribution to the scientific understanding of the human response to TCDD and related compounds. By every measure, human hepatocytes responded qualitatively and quantitatively differently to TCDD. Quantitatively, human hepatocytes were less sensitive than rat hepatocytes. Qualitatively, the discordantly affect cellular pathways may provide important clues to the MOA for TCDD-induced hepatotoxicity and insight into the lack of hepatotoxicity observed in human epidemiology studies. Future studies will need to incorporate time course changes in expression and compare the in vitro effects with those observed in vivo. Nonetheless, the results from the study have provided useful information for deriving species-specific uncertainty factors and relative potency assessments that can be used in the risk assessment of TCDD.
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